<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROPAFENONE HYDROCHLORIDE - propafenone hydrochloride tablet, film coated </strong><br>Physicians Total Care, Inc.<br></p></div>
<h1>PROPAFENONE HYDROCHLORIDE TABLETS</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Propafenone hydrochloride is an antiarrhythmic drug supplied in scored, film-coated tablets of 150, 225 and 300 mg for oral administration. Propafenone has some structural similarities to beta-blocking agents.</p>
<p>The structural formula of propafenone hydrochloride is given below:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a7c8f090-c48c-44f7-9973-2cf4b491e35c&amp;name=propafenone-01.jpg"></div>
<p>2'-[2-Hydroxy-3-(propylamino)-propoxy]-3-phenylpropiophenone hydrochloride</p>
<p>Propafenone hydrochloride occurs as colorless crystals or white crystalline powder with a very bitter taste. It is slightly soluble in water (20°C), chloroform and ethanol. The following inactive ingredients are contained in the tablet: carnauba wax, hypromellose, magnesium stearate, polydextrose, polyethylene glycol, polysorbate 80, povidone, pregelatinized starch (corn), propylene glycol, sodium starch glycolate, titanium dioxide, and triacetin.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="clin"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Propafenone is a Class 1C antiarrhythmic drug with local anesthetic effects, and a direct stabilizing action on myocardial membranes. The electrophysiological effect of propafenone manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions. Diastolic <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitability</span> threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity.</p>
<p>Studies in anesthetized dogs and isolated organ preparations show that propafenone has beta-sympatholytic activity at about 1/50 the potency of propranolol. Clinical studies employing isoproterenol challenge and exercise testing after single doses of propafenone indicate a beta-adrenergic blocking potency (per mg) about 1/40 that of propranolol in man. In clinical trials, resting heart rate decreases of about 8% were noted at the higher end of the therapeutic plasma concentration range. At very high concentrations <span class="Italics">in vitro</span>, propafenone can inhibit the slow inward current carried by calcium, but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy. Propafenone has local anesthetic activity approximately equal to procaine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.2"></a><p></p>
<h2>Electrophysiology</h2>
<p class="First">Electrophysiology studies in patients with <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> (VT) have shown that propafenone HCl prolongs atrioventricular (AV) conduction while having little or no effect on sinus node function. Both AV nodal conduction time (AH interval) and His-Purkinje conduction time (HV interval) are prolonged. Propafenone has little or no effect on the atrial functional refractory period, but AV nodal functional and effective refractory periods are prolonged. In patients with Wolff-Parkinson-White (WPW) syndrome, propafenone reduces conduction and increases the effective refractory period of the accessory pathway in both directions. Propafenone slows conduction and consequently produces dose-related changes in the PR interval and QRS duration. QTc interval does not change.</p>
<a name="i8ff96f51-c84b-4c3b-804b-4bb1653d8d7e"></a><table width="80%">
<caption><span>Mean Changes in ECG Intervals<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="12%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="11%">
<col align="center" valign="top" width="11%">
<thead>
<tr class="Botrule First Toprule"><th class="Botrule" align="center" colspan="9">Total Daily Dose (mg)</th></tr>
<tr class="BotRule">
<th class="Lrule" align="left"></th>
<th class="Lrule" align="center" colspan="2">337.5 mg</th>
<th class="Lrule" align="center" colspan="2">450 mg</th>
<th class="Lrule" align="center" colspan="2">675 mg</th>
<th class="Lrule Rrule" align="center" colspan="2">900 mg</th>
</tr>
<tr class="Last">
<th class="Lrule" align="left">Interval</th>
<th class="Lrule" align="center">msec</th>
<th class="Lrule" align="center">%</th>
<th class="Lrule" align="center">msec</th>
<th class="Lrule" align="center">%</th>
<th class="Lrule" align="center">msec</th>
<th class="Lrule" align="center">%</th>
<th class="Lrule" align="center">msec</th>
<th class="Lrule Rrule" align="center">%</th>
</tr>
</thead>
<tfoot><tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Change and percent change based on mean baseline values for each treatment group.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="BotRule First">
<td class="Lrule" align="left">RR</td>
<td class="Lrule" align="center">−14.5</td>
<td class="Lrule" align="center">−1.8</td>
<td class="Lrule" align="center">30.6</td>
<td class="Lrule" align="center">3.8</td>
<td class="Lrule" align="center">31.5</td>
<td class="Lrule" align="center">3.9</td>
<td class="Lrule" align="center">41.7</td>
<td class="Lrule Rrule" align="center">5.1</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left">PR</td>
<td class="Lrule" align="center">3.6</td>
<td class="Lrule" align="center">2.1</td>
<td class="Lrule" align="center">19.1</td>
<td class="Lrule" align="center">11.6</td>
<td class="Lrule" align="center">28.9</td>
<td class="Lrule" align="center">17.8</td>
<td class="Lrule" align="center">35.6</td>
<td class="Lrule Rrule" align="center">21.9</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left">QRS</td>
<td class="Lrule" align="center">5.6</td>
<td class="Lrule" align="center">6.4</td>
<td class="Lrule" align="center">5.5</td>
<td class="Lrule" align="center">6.1</td>
<td class="Lrule" align="center">7.7</td>
<td class="Lrule" align="center">8.4</td>
<td class="Lrule" align="center">15.6</td>
<td class="Lrule Rrule" align="center">17.3</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">QTc</td>
<td class="Lrule" align="center">2.7</td>
<td class="Lrule" align="center">0.7</td>
<td class="Lrule" align="center">−7.5</td>
<td class="Lrule" align="center">−1.8</td>
<td class="Lrule" align="center">5.0</td>
<td class="Lrule" align="center">1.2</td>
<td class="Lrule" align="center">14.7</td>
<td class="Lrule Rrule" align="center">3.7</td>
</tr>
</tbody>
</table>
<p>In any individual patient, the above ECG changes cannot be readily used to predict either efficacy or plasma concentration.</p>
<p>Propafenone causes a dose-related and concentration-related decrease in the rate of single and multiple <span class="product-label-link" type="condition" conceptid="4008580" conceptname="Ventricular bigeminy">premature ventricular contractions</span> (PVCs) and can suppress recurrence of <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>. Based on the percent of patients attaining substantial (80–90%) suppression of ventricular ectopic activity, it appears that trough plasma levels of 0.2 to 1.5 µg/mL can provide good suppression, with higher concentrations giving a greater rate of good response.</p>
<p>When 600 mg/day propafenone was administered to patients with paroxysmal atrial <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmias</span>, mean heart rate during <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> decreased 14 beats/min and 37 beats/min for <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">paroxysmal atrial fibrillation</span>/flutter (PAF) patients and <span class="product-label-link" type="condition" conceptid="317893" conceptname="Paroxysmal supraventricular tachycardia">paroxysmal supraventricular tachycardia</span> (PSVT) patients, respectively.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-3.3"></a><p></p>
<h2>Hemodynamics</h2>
<p class="First">Sympathetic stimulation may be a vital component supporting circulatory function in patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, and its inhibition by the beta blockade produced by propafenone HCl may in itself aggravate <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>.</p>
<p>Additionally, like other Class 1C antiarrhythmic drugs, studies in humans have shown that propafenone HCl exerts a negative inotropic effect on the myocardium. Cardiac catheterization studies in patients with moderately impaired ventricular function (mean C.I. = 2.61 L/min/m<span class="Sup">2</span>) utilizing intravenous propafenone infusions (2 mg/kg over 10 min+2 mg/min for 30 min) that gave mean plasma concentrations of 3.0 µg/mL (well above the therapeutic range of 0.2–1.5 µg/mL) showed significant increases in pulmonary capillary wedge pressure, systemic and pulmonary <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistances</span> and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> and <span class="product-label-link" type="condition" conceptid="4208254" conceptname="Cardiac index">cardiac index</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.4"></a><p></p>
<h2>Pharmacokinetics and Metabolism</h2>
<p class="First">Propafenone HCl is nearly completely absorbed after oral administration with peak plasma levels occurring approximately 3.5 hours after administration in most individuals. Propafenone exhibits extensive saturable presystemic biotransformation (first pass effect) resulting in a dose dependent and dosage form dependent absolute bioavailability; e.g., a 150 mg tablet had absolute bioavailability of 3.4%, while a 300 mg tablet had absolute bioavailability of 10.6%. A 300 mg solution which was rapidly absorbed, had absolute bioavailability of 21.4%. At still larger doses, above those recommended, bioavailability increases still further. Decreased liver function also increases bioavailability; bioavailability is inversely related to indocyanine green clearance reaching 60–70% at clearances of 7 mL/min and below. The clearance of propafenone is reduced and the elimination half-life increased in patients with significant hepatic dysfunction (see <span class="Bold"><a href="#precau">PRECAUTIONS</a></span>).</p>
<p>Propafenone HCl follows a nonlinear pharmacokinetic disposition presumably due to saturation of first pass hepatic metabolism as the liver is exposed to higher concentrations of propafenone and shows a very high degree of interindividual variability. For example, for a three-fold increase in daily dose from 300 to 900 mg/day there is a tenfold increase in steady-state plasma concentration. The top 25% of patients given 375 mg/day, however, had a mean concentration of propafenone larger than the bottom 25%, and about equal to the second 25%, of patients given a dose of 900 mg. Although food increased peak blood level and bioavailability in a single dose study, during multiple dose administration of propafenone to healthy volunteers food did not change bioavailability significantly.</p>
<p>There are two genetically determined patterns of propafenone metabolism. In over 90% of patients, the drug is rapidly and extensively metabolized with an elimination half-life from 2–10 hours. These patients metabolize propafenone into two active metabolites: 5-hydroxypropafenone which is formed by CYP2D6 and N-depropylpropafenone which is formed by both CYP3A4 and CYP1A2.</p>
<p><span class="Italics">In vitro</span> preparations have shown these two metabolites to have antiarrhythmic activity comparable to propafenone but in man they both are usually present in concentrations less than 20% of propafenone. Nine additional metabolites have been identified, most in only trace amounts. It is the saturable hydroxylation pathway that is responsible for nonlinear pharmacokinetic disposition.</p>
<p>In less than 10% of patients (and in any patient also receiving quinidine, see <span class="Bold"><a href="#precau">PRECAUTIONS</a></span>), metabolism of propafenone is slower because the 5-hydroxy metabolite is not formed or is minimally formed. The estimated propafenone elimination half-life ranges from 10–32 hours. Decreased ability to form the 5-hydroxy metabolite of propafenone is associated with a diminished ability to metabolize debrisoquine and a variety of other drugs (encainide, metoprolol, dextromethorphan). In these patients, the N-depropylpropafenone occurs in quantities comparable to the levels occurring in extensive metabolizers. In slow metabolizers propafenone pharmacokinetics are linear.</p>
<p>There are significant differences in plasma concentrations of propafenone in slow and extensive metabolizers, the former achieving concentrations 1.5 to 2.0 times those of the extensive metabolizers at daily doses of 675–900 mg/day. At low doses the differences are greater, with slow metabolizers attaining concentrations more than five times that of extensive metabolizers. Because the difference decreases at high doses and is mitigated by the lack of the active 5-hydroxy metabolite in the slow metabolizers, and because steady-state conditions are achieved after 4–5 days of dosing in all patients, the recommended dosing regimen is the same for all patients. The greater variability in blood levels require that the drug be titrated carefully in patients with close attention paid to clinical and ECG evidence of toxicity (See <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>).</p>
<p><span class="Italics">In vitro</span> and <span class="Italics">in vivo</span> studies have shown that the R-isomer of propafenone is cleared faster than the S-isomer via the 5-hydroxylation pathway (CYP2D6). This results in a higher ratio of S-propafenone during steady state.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-4"></a><p></p>
<h1>Clinical Trials</h1>
<p class="First">In two randomized, crossover, placebo-controlled, double-blind trials of 60–90 days duration in patients with paroxysmal supraventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> [<span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">paroxysmal atrial fibrillation</span>/flutter (PAF), or <span class="product-label-link" type="condition" conceptid="317893" conceptname="Paroxysmal supraventricular tachycardia">paroxysmal supraventricular tachycardia</span> (PSVT)], propafenone reduced the rate of both <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, as shown in the following table:</p>
<a name="i879118cb-e4d5-4ddd-8890-370c10d45ac4"></a><table width="90%">
<col align="left" valign="top" width="34%">
<col align="center" valign="bottom" width="18%">
<col align="center" valign="bottom" width="15%">
<col align="center" valign="bottom" width="18%">
<col align="center" valign="bottom" width="15%">
<thead>
<tr class="First TopRule">
<th class="Rrule" align="left"></th>
<th class="BotRule Rrule TopRule" align="center" colspan="2">Study 1</th>
<th class="BotRule Lrule Rrule TopRule" align="center" colspan="2">Study 2</th>
</tr>
<tr class="Last">
<th class="Rrule" align="left"></th>
<th class="Rrule" align="center">Propafenone</th>
<th class="Rrule" align="center">Placebo</th>
<th class="Rrule" align="center">Propafenone</th>
<th class="Lrule Rrule" align="center">Placebo</th>
</tr>
</thead>
<tbody>
<tr class="First">
<td class="Lrule" align="left">PAF</td>
<td class="Lrule" align="center">n=30</td>
<td class="Lrule" align="center">n=30</td>
<td class="Lrule" align="center">n=9</td>
<td class="Lrule Rrule" align="center">n=9</td>
</tr>
<tr>
<td class="Lrule" align="left">  Percent attack free</td>
<td class="Lrule" align="center">53%</td>
<td class="Lrule" align="center">13%</td>
<td class="Lrule" align="center">67%</td>
<td class="Lrule Rrule" align="center">22%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left">  Median time to first recurrence</td>
<td class="Lrule" align="center">&gt;98 days</td>
<td class="Lrule" align="center">8 days</td>
<td class="Lrule" align="center">62 days</td>
<td class="Lrule Rrule" align="center">5 days</td>
</tr>
<tr>
<td class="Lrule" align="left">PSVT</td>
<td class="Lrule" align="center">n=45</td>
<td class="Lrule" align="center">n=45</td>
<td class="Lrule" align="center">n=15</td>
<td class="Lrule Rrule" align="center">n=15</td>
</tr>
<tr>
<td class="Lrule" align="left">  Percent attack free</td>
<td class="Lrule" align="center">47%</td>
<td class="Lrule" align="center">16%</td>
<td class="Lrule" align="center">38%</td>
<td class="Lrule Rrule" align="center">7%</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">  Median time to first recurrence</td>
<td class="Lrule" align="center">&gt;98 days</td>
<td class="Lrule" align="center">12 days</td>
<td class="Lrule" align="center">31 days</td>
<td class="Lrule Rrule" align="center">8 days</td>
</tr>
</tbody>
</table>
<p>The patient population in the above trials was 50% male with a mean age of 57.3 years. Fifty percent of the patients had a diagnosis of PAF and 50% had PSVT. Eighty percent of the patients received 600 mg/day propafenone. No patient died in the above 2 studies.</p>
<p>In U.S. long-term safety trials, 474 patients (mean age: 57.4 ± 14.5 years) with supraventricular <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span> [195 with PAF, 274 with PSVT and 5 with both PAF and PSVT] were treated up to 5 years (mean: 14.4 months) with propafenone. Fourteen of the patients died. When this mortality rate was compared to the rate in a similar patient population (n=194 patients; mean age: 43.0 ± 16.8 years) studied in an <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> clinic, there was no age-adjusted difference in mortality. This comparison was not, however, a randomized trial and the 95% confidence interval around the comparison was large, such that neither a significant adverse or favorable effect could be ruled out.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">In patients without structural heart disease, propafenone is indicated to prolong the time to recurrence of</p>
<dl>
<dt>–</dt>
<dd><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">paroxysmal atrial fibrillation</span>/flutter (PAF) associated with disabling symptoms.</dd>
<dt>–</dt>
<dd><span class="product-label-link" type="condition" conceptid="317893" conceptname="Paroxysmal supraventricular tachycardia">paroxysmal supraventricular tachycardia</span> (PSVT) associated with disabling symptoms.</dd>
</dl>
<p>As with other agents, some patients with <span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">atrial flutter</span> treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended.</p>
<p>The use of propafenone HCl in patients with <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">chronic atrial fibrillation</span> has not been evaluated. Propafenone HCl should not be used to control ventricular rate during <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>.</p>
<p>Propafenone HCl is also indicated for the treatment of</p>
<dl>
<dt>–</dt>
<dd>documented <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, such as <span class="Underline">sustained</span> <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, that, in the judgment of the physician, are life-threatening. Because of the <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">proarrhythmic effects</span> of propafenone HCl, its use with lesser <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks.</dd>
</dl>
<p>Initiation of propafenone HCl treatment, as with other antiarrhythmics used to treat life-threatening <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, should be carried out in the hospital.</p>
<p>Propafenone HCl, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or <span class="product-label-link" type="condition" conceptid="4021776" conceptname="Atrial rhythm">atrial arrhythmias</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Propafenone HCl is contraindicated in the presence of uncontrolled <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>, sinoatrial, atrioventricular and intraventricular disorders of impulse generation and/or conduction (e.g., sick sinus node syndrome, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>) in the absence of an artificial pacemaker, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, marked <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, bronchospastic disorders, manifest <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span>, and known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to the drug.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-7"></a><p></p>
<h1>WARNINGS</h1>
<a name="i8e2f879a-c761-4f3b-805b-467da4810256"></a><table width="100%">
<col align="left" valign="top" width="100%">
<tbody class="Headless">
<tr class="First"><td class="Lrule Rrule" align="left"><span class="Bold">Mortality</span></td></tr>
<tr><td class="Lrule Rrule" align="left"><span class="Bold">In the National Heart, Lung and Blood Institute's <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Cardiac Arrhythmia</span> Suppression Trial (CAST), a long-term, multi-center, randomized, double-blind study in patients with asymptomatic non-life-threatening <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> who had a <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span> more than six days but less than two years previously, an increased rate of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> or reversed <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> rate (7.7%; 56/730) was seen in patients treated with encainide or flecainide (class 1C antiarrhythmics) compared with that seen in patients assigned to placebo (3.0%; 22/725). The average duration of treatment with encainide or flecainide in this study was ten months.</span></td></tr>
<tr class="Last"><td class="Lrule Rrule" align="left"><span class="Bold">The applicability of the CAST results to other populations (e.g., those without recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>) or other antiarrhythmic drugs is uncertain, but at present it is prudent to consider any 1C antiarrhythmic to have a significant risk in patients with structural heart disease. Given the lack of any evidence that these drugs improve survival, antiarrhythmic agents should generally be avoided in patients with non-life-threatening <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>, even if the patients are experiencing unpleasant, but not life-threatening, symptoms or signs.</span></td></tr>
</tbody>
</table>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Proarrhythmic Effects</span></h2>
<p class="First">Propafenone HCl, like other antiarrhythmic agents, may cause new or worsened <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>. Such <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">proarrhythmic effects</span> range from an increase in frequency of PVCs to the development of more severe <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span>, <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> or <span class="product-label-link" type="condition" conceptid="4135823" conceptname="Torsades de pointes">torsade de pointes</span>; i.e., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> that is more sustained or more rapid which may lead to fatal consequences. It is therefore essential that each patient given propafenone HCl be evaluated electrocardiographically and clinically prior to, and during therapy to determine whether the response to propafenone HCl supports continued treatment.</p>
<p>Overall in clinical trials with propafenone, 4.7% of all patients had new or worsened <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> possibly representing a pro-arrhythmic event (0.7% was an increase in PVCs; 4.0% a worsening, or new appearance, of VT or <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> [VF]). Of the patients who had worsening of VT (4%), 92% had a history of VT and/or VT/VF, 71% had <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, and 68% had a prior <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>. The incidence of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">proarrhythmia</span> in patients with less serious or benign <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmias</span>, which include patients with an increase in frequency of PVCs, was 1.6%. Although most proarrhythmic events occurred during the first week of therapy, late events also were seen and the CAST study (see above) suggests that an increased risk is present throughout treatment.</p>
<p>In the 474 patient U.S. multicenter trial in patients with symptomatic <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span> (SVT), 1.9% (9/474) of these patients experienced <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> (VT) or <span class="product-label-link" type="condition" conceptid="437894" conceptname="Ventricular fibrillation">ventricular fibrillation</span> (VF) during the study. However, in 4 of the 9 patients, the <span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">ventricular tachycardia</span> was of atrial origin. Six of the nine patients that developed <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span> did so within 14 days of onset of therapy. About 2.3% (11/474) of all patients had a recurrence of SVT during the study which could have been a change in the patients' <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span> behavior or could represent a proarrhythmic event. Case reports in patients treated with propafenone HCl for <span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">atrial fibrillation</span>/flutter have included increased PVCs, VT, VF, and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.2"></a><p></p>
<h2>Nonallergic <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> (e.g., <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>)</h2>
<p class="First">PATIENTS WITH BRONCHOSPASTIC DISEASE SHOULD, IN GENERAL, NOT RECEIVE PROPAFENONE or other agents with beta-adrenergic-blocking activity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive Heart Failure</span></h2>
<p class="First">During treatment with oral propafenone in patients with depressed baseline function (mean <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> (EF)=33.5%), no significant decreases in <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> were seen. In clinical trial experience, new or worsened CHF has been reported in 3.7% of patients with <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>; of those 0.9% were considered probably or definitely related to propafenone HCl. Of the patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> probably related to propafenone, 80% had preexisting <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> and 85% had <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>. CHF attributable to propafenone HCl developed rarely (&lt;0.2%) in <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> patients who had no previous history of CHF. CHF occurred in 1.9% of patients studied with PAF or PSVT.</p>
<p>As propafenone HCl exerts both beta blockade and a (dose-related) negative inotropic effect on cardiac muscle, patients with <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> should be fully compensated before receiving propafenone HCl. If <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> worsens, propafenone HCl should be discontinued (unless <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> is due to the <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmia</span>) and, if indicated, restarted at a lower dosage only after adequate cardiac compensation has been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>Conduction Disturbances</h2>
<p class="First">Propafenone HCl slows atrioventricular conduction and also causes first degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>. Average PR interval prolongation and increases in QRS duration are closely correlated with dosage increases and concomitant increases in propafenone plasma concentrations. The incidence of first degree, second degree, and <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">third degree AV block</span> observed in 2,127 <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> patients was 2.5%, 0.6%, and 0.2%, respectively. Development of second or <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">third degree AV block</span> requires a reduction in dosage or discontinuation of propafenone HCl. <span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">Bundle branch block</span> (1.2%) and intraventricular conduction delay (1.1%) have been reported in patients receiving propafenone. <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span> has also been reported (1.5%). Experience in patients with sick sinus node syndrome is limited and these patients should not be treated with propafenone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5"></a><p></p>
<h2>Effects on Pacemaker Threshold</h2>
<p class="First">Propafenone HCl may alter both pacing and sensing thresholds of artificial pacemakers. Pacemakers should be monitored and programmed accordingly during therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.6"></a><p></p>
<h2>Hematologic Disturbances</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span> (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, and <span class="product-label-link" type="condition" conceptid="320073" conceptname="Neutropenia">neutropenia</span>) has been reported in patients receiving propafenone. Generally, the <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> occurred within the first two months of propafenone therapy and upon discontinuation of therapy, the white count usually normalized by 14 days. Unexplained <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and/or decrease in white cell count, particularly during the initial three months of therapy, warrant consideration of possible <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>/<span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>. Patients should be instructed to promptly report the development of any signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> such as <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, or <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">chills</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="precau"></a><a name="section-8"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1"></a><p></p>
<h2>Hepatic Dysfunction</h2>
<p class="First">Propafenone is highly metabolized by the liver and should, therefore, be administered cautiously to patients with impaired hepatic function. Severe liver dysfunction increases the bioavailability of propafenone to approximately 70% compared to 3–40% for patients with normal liver function. In eight patients with moderate to severe liver disease, the mean half-life was approximately 9 hours. As a result, the dose of propafenone given to patients with impaired hepatic function should be approximately 20–30% of the dose given to patients with normal hepatic function (see <span class="Bold"><a href="#dosage">DOSAGE AND ADMINISTRATION</a></span>). Careful monitoring for excessive pharmacological effects (see <span class="Bold"><a href="#over">OVERDOSAGE</a></span>) should be carried out.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.2"></a><p></p>
<h2>Renal Dysfunction</h2>
<p class="First">A considerable percentage of propafenone metabolites (18.5%–38% of the dose/48 hours) are excreted in the urine.</p>
<p>Until further data are available, propafenone HCl should be administered cautiously to patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. These patients should be carefully monitored for signs of overdosage (see <span class="Bold"><a href="#over">OVERDOSAGE</a></span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.3"></a><p></p>
<h2>Elevated ANA Titers</h2>
<p class="First">Positive ANA titers have been reported in patients receiving propafenone. They have been reversible upon cessation of treatment and may disappear even in the face of continued propafenone therapy. These laboratory findings were usually not associated with clinical symptoms, but there is one published case of drug-induced lupus erythematosis (positive rechallenge); it resolved completely upon discontinuation of therapy. Patients who develop an abnormal ANA test should be carefully evaluated and, if persistent or worsening elevation of ANA titers is detected, consideration should be given to discontinuing therapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="impaired"></a><a name="section-8.4"></a><p></p>
<h2>Impaired Spermatogenesis</h2>
<p class="First">Reversible disorders of spermatogenesis have been demonstrated in monkeys, dogs and rabbits after high dose intravenous administration of propafenone HCl. Evaluation of the effects of short-term propafenone administration on spermatogenesis in 11 normal subjects suggests that propafenone HCl produced a reversible, short-term drop (within normal range) in sperm count. Subsequent evaluations in 11 patients receiving propafenone chronically have suggested no effect of propafenone HCl on sperm count.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.5"></a><p></p>
<h2>Neuromuscular Dysfunction</h2>
<p class="First">Exacerbation of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> has been reported during propafenone therapy.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-8.6"></a><p></p>
<h2>Drug Interactions</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.1"></a><p></p>
<h3>Quinidine</h3>
<p class="First">Small doses of quinidine completely inhibit the hydroxylation metabolic pathway, making all patients, in effect, slow metabolizers (see <span class="Bold"><a href="#clin">CLINICAL PHARMACOLOGY</a></span>). There is, as yet, too little information to recommend concomitant use of propafenone and quinidine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.2"></a><p></p>
<h3>Local Anesthetics</h3>
<p class="First">Concomitant use of local anesthetics (i.e., during pacemaker implantations, surgery, or dental use) may increase the risks of central nervous system side effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.3"></a><p></p>
<h3>Digitalis</h3>
<p class="First">Propafenone hydrochloride produces dose-related increases in serum digoxin levels ranging from about 35% at 450 mg/day to 85% at 900 mg/day of propafenone without affecting digoxin renal clearance. These elevations of digoxin levels were maintained for up to 16 months during concomitant administration. Plasma digoxin levels of patients on concomitant therapy should be measured, and digoxin dosage should ordinarily be reduced when propafenone is started, especially if a relatively large digoxin dose is used or if plasma concentrations are relatively high.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.4"></a><p></p>
<h3>Beta-Antagonists</h3>
<p class="First">In a study involving healthy subjects, concomitant administration of propafenone and propranolol has resulted in substantial increases in propranolol plasma concentration and elimination half-life with no change in propafenone plasma levels from control values. Similar observations have been reported with metoprolol. Propafenone appears to inhibit the hydroxylation pathway for the two beta-antagonists (just as quinidine inhibits propafenone metabolism). Increased plasma concentrations of metoprolol could overcome its relative cardioselectivity. In propafenone clinical trials, patients who were receiving beta-blockers concurrently did not experience an increased incidence of side effects. While the therapeutic range for beta-blockers is wide, a reduction in dosage may be necessary during concomitant administration with propafenone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.5"></a><p></p>
<h3>Warfarin</h3>
<p class="First">In a study of eight healthy subjects receiving propafenone and warfarin concomitantly, mean steady-state warfarin plasma concentrations increased 39% with a corresponding increase in <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times of approximately 25%. It is therefore recommended that <span class="product-label-link" type="condition" conceptid="4173906" conceptname="Clotting factor II assay">prothrombin</span> times be routinely monitored and the dose of warfarin be adjusted if necessary.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.6"></a><p></p>
<h3>Cimetidine</h3>
<p class="First">Concomitant administration of propafenone and cimetidine in 12 healthy subjects resulted in a 20% increase in steady-state plasma concentrations of propafenone with no detectable changes in electrocardiographic parameters beyond that measured on propafenone alone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.7"></a><p></p>
<h3>Desipramine</h3>
<p class="First">Concomitant administration of propafenone and desipramine may result in elevated serum desipramine levels. Both desipramine, a tricyclic antidepressant, and propafenone are cleared by oxidative pathways of demthylation and hydroxylation carried out by the hepatic P-450 cytochrome.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.8"></a><p></p>
<h3>Cyclosporin</h3>
<p class="First">Propafenone therapy may increase levels of cyclosporin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.9"></a><p></p>
<h3>Theophylline</h3>
<p class="First">Propafenone may increase theophylline concentration during concomitant therapy with the development of theophylline toxicity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.10"></a><p></p>
<h3>Rifampin</h3>
<p class="First">Rifampin may accelerate the metabolism and decrease the plasma levels and antiarrhythmic efficacy of propafenone.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.6.11"></a><p></p>
<h3>Other</h3>
<p class="First">Limited experience with propafenone combined with calcium antagonists and diuretics has been reported without evidence of clinically significant adverse reactions. Drugs that inhibit CYP2D6, CYP1A2 and CYP3A4 might lead to increased plasma levels of propafenone. When propafenone is administered with inhibitors of these enzymes, the patients should be closely monitored and the dose adjusted accordingly.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.7"></a><p></p>
<h2>Renal and Hepatic Toxicity in Animals</h2>
<p class="First">Renal changes have been observed in the rat following 6 months of oral administration of propafenone HCl at doses of 180 and 360 mg/kg/day (about 2 and 4 times, respectively, the maximum recommended human daily dose [MRHD] on a mg/m<span class="Sup">2</span> basis). Both inflammatory and non-inflammatory changes in the renal tubules, with accompanying interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span>, were observed. These changes were reversible, as they were not found in rats allowed to recover for 6 weeks. Fatty degenerative changes of the liver were found in rats following longer durations of administration of propafenone HCl at a dose of 270 mg/kg/day (about 3 times the MRHD on a mg/m<span class="Sup">2</span> basis). There were no renal or hepatic changes at 90 mg/kg/day (equivalent to the MRHD on a mg/m<span class="Sup">2</span> basis).</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-8.8"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">Lifetime maximally tolerated oral dose studies in mice (up to 360 mg/kg/day, about twice the maximum recommended human oral daily dose [MRHD] on a mg/m<span class="Sup">2</span> basis) and rats (up to 270 mg/kg/day, about 3 times the MRHD on a mg/m<span class="Sup">2</span> basis) provided no evidence of a carcinogenic potential for propafenone HCl.</p>
<p>Propafenone HCl tested negative for mutagenicity in the Ames (<span class="product-label-link" type="condition" conceptid="4235289" conceptname="Salmonellosis">salmonella</span>) test and the mouse dominant lethal test, and tested negative for clastogenicity in the Chinese hamster micronucleus test, and other <span class="Italics">in vivo</span> tests for chromosomal aberrations in rat bone marrow and Chinese hamster bone marrow and spermatogonia.</p>
<p>Propafenone HCl, administered intravenously to rabbits, dogs, and monkeys has been shown to decrease spermatogenesis. These effects were reversible, were not found following oral dosing of propafenone HCl, were seen at lethal or near lethal dose levels and were not seen in rats treated either orally or intravenously (see <span class="Bold"><a href="#impaired">PRECAUTIONS, Impaired Spermatogenesis</a></span>). Treatment of male rabbits for 10 weeks prior to mating at an oral dose of 120 mg/kg/day (about 2.4 times the MRHD on a mg/m<span class="Sup">2</span> basis) or an intravenous dose of 3.5 mg/kg/day (a spermatogenesis-impairing dose) did not result in evidence of impaired fertility. Nor was there evidence of impaired fertility when propafenone HCl was administered orally to male and female rats at dose levels up to 270 mg/kg/day (about 3 times the MRHD on a mg/m<span class="Sup">2</span> basis).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-8.9"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.9.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.9.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First">Propafenone HCl has been shown to be embryotoxic (decreased survival) in rabbits and rats when given in oral maternally toxic doses of 150 mg/kg/day (about 3 times the maximum recommended human dose [MRHD] on a mg/m<span class="Sup">2</span> basis) and 600 mg/kg/day (about 6 times the MRHD on a mg/m<span class="Sup">2</span> basis, respectively. Although maternally tolerated doses (up to 270 mg/kg/day, about 3 times the MRHD on a mg/m<span class="Sup">2</span> basis) produced no evidence of embryotoxicity in rats, post-implantation loss was elevated in all rabbit treatment groups (doses as low as 15 mg/kg/day, about 1/3 the MRHD on a mg/m<span class="Sup">2</span> basis). There are no adequate and well-controlled studies in pregnant women. Propafenone HCl should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34078-6">
<a name="section-8.9.2"></a><p></p>
<h3>Non-teratogenic Effects</h3>
<p class="First">In a study in which female rats received daily oral doses of propafenone HCl from mid-gestation through weaning of their offspring, doses as low as 90 mg/kg/day (equivalent to the MRHD on a mg/m<span class="Sup">2</span> basis) produced increases in maternal <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>. Doses of 360 or more mg/kg/day (4 or more times the MRHD on a mg/m<span class="Sup">2</span> basis) resulted in reductions in neonatal survival, body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> and physiological development.</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="section-8.10"></a><p></p>
<h2>Labor and Delivery</h2>
<p class="First">It is not known whether the use of propafenone during labor or delivery has immediate or delayed adverse effects on the fetus, or whether it prolongs the duration of labor or increases the need for forceps delivery or other obstetrical intervention.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-8.11"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from propafenone HCl, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-8.12"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">The safety and effectiveness of propafenone HCl in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-8.13"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of propafenone HCl did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-9"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions associated with propafenone HCl occur most frequently in the gastrointestinal, cardiovascular, and central nervous systems. About 20% of patients treated with propafenone HCl have discontinued treatment because of adverse reactions.</p>
<p>Adverse reactions reported for &gt;1.5% of 474 SVT patients who received propafenone in U.S. clinical trials are presented in the following table by incidence and percent discontinuation, reported to the nearest percent.</p>
<a name="i138e79ff-293c-46f0-8a5e-f69457cb38ef"></a><table width="80%">
<caption><span>Adverse Reactions Reported for &gt;1.5% of SVT Patients</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="30%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last TopRule">
<th class="Rrule" align="left"></th>
<th class="Rrule TopRule" align="center">Incidence<br>(N=480)</th>
<th class="Lrule Rrule TopRule" align="center">% of Patients Who Discontinued</th>
</tr></thead>
<tbody>
<tr class="BotRule First">
<td class="Lrule" align="left">Unusual taste</td>
<td class="Lrule" align="center">14%</td>
<td class="Lrule Rrule" align="center">1.3%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule" align="center">11%</td>
<td class="Lrule Rrule" align="center">2.9%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule" align="center">9%</td>
<td class="Lrule Rrule" align="center">1.7%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Lrule" align="center">8%</td>
<td class="Lrule Rrule" align="center">0.2%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Lrule" align="center">6%</td>
<td class="Lrule Rrule" align="center">0.8%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Lrule" align="center">6%</td>
<td class="Lrule Rrule" align="center">1.5%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred Vision</span></td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule Rrule" align="center">0.6%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span></td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule Rrule" align="center">1.3%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">1.0%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">Wide Complex Tachycardia</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">1.9%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left">CHF</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.6%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.2%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.2%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.4%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.2%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.4%</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.0%</td>
</tr>
</tbody>
</table>
<p>Results of controlled trials in <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> patients comparing adverse reaction rates on propafenone and placebo, and on propafenone and quinidine are shown in the following table. Adverse reactions reported for ≥1% of the patients receiving propafenone as shown, unless they were more frequent on placebo than propafenone. The most common events were unusual taste, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, first degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, intraventricular conduction delay, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> was relatively common also, but was not increased compared to placebo.</p>
<a name="i8ab54330-8fd4-4486-8329-d9aa17cc45cb"></a><table width="80%">
<caption><span>Adverse Reactions Reported for ≥1% of <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmia</span> Patients</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead>
<tr class="First TopRule">
<th class="Rrule" align="left"></th>
<th class="BotRule Rrule TopRule" align="center" colspan="2">Prop./Placebo Trials</th>
<th class="BotRule Lrule Rrule TopRule" align="center" colspan="2">Prop./Quinidine Trial</th>
</tr>
<tr>
<th class="Rrule" align="left"></th>
<th class="BotRule Rrule" align="center">Prop.</th>
<th class="BotRule Rrule" align="center">Placebo</th>
<th class="BotRule Rrule" align="center">Prop.</th>
<th class="BotRule Lrule Rrule" align="center">Quinidine</th>
</tr>
<tr class="Last">
<th class="BotRule Rrule" align="left"></th>
<th class="BotRule Rrule" align="center">(N=247)</th>
<th class="BotRule Rrule" align="center">(N=111)</th>
<th class="BotRule Rrule" align="center">(N=53)</th>
<th class="BotRule Lrule Rrule" align="center">(N=52)</th>
</tr>
</thead>
<tbody>
<tr class="BotRule First">
<td class="Lrule" align="left">Unusual Taste</td>
<td class="Lrule" align="center">7%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">23%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule" align="center">7%</td>
<td class="Lrule" align="center">5%</td>
<td class="Lrule" align="center">15%</td>
<td class="Lrule Rrule" align="center">10%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left">First Degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV Block</span></td>
<td class="Lrule" align="center">5%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>(s)</td>
<td class="Lrule" align="center">5%</td>
<td class="Lrule" align="center">5%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">8%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Lrule" align="center">4%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">6%</td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left">Intraventricular Conduction Delay</td>
<td class="Lrule" align="center">4%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">-</td>
<td class="Lrule Rrule" align="center">-</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">6%</td>
<td class="Lrule Rrule" align="center">15%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">4%</td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">-</td>
<td class="Lrule Rrule" align="center">-</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred Vision</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">6%</td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">6%</td>
<td class="Lrule Rrule" align="center">6%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">4%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span>/<span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Cramps</span></td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">8%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">8%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left">CHF</td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">10%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span></td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left">Vision, Abnormal</td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">Esophagitis</span></td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span></td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">-</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">-</td>
<td class="Lrule Rrule" align="center">-</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Proarrhythmia</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left">Angina</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">4%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left">Second Degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV Block</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">-</td>
<td class="Lrule Rrule" align="center">-</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">Bundle Branch Block</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">2%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left">Loss of Balance</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">-</td>
<td class="Lrule Rrule" align="center">-</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">6%</td>
<td class="Lrule Rrule" align="center">39%</td>
</tr>
</tbody>
</table>
<p>Adverse reactions reported for ≥1% of 2,127 <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> patients who received propafenone in U.S. clinical trials are presented in the following table by propafenone daily dose. The most common adverse reactions in controlled clinical trials appeared dose-related (but note that most patients spent more time at the larger doses), especially <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, unusual taste, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>, and <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. Some less common reactions may also have been dose-related such as first degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, and <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>. The principal causes of discontinuation were the most common events and are shown in the table.</p>
<a name="iac958f25-6eac-474b-807b-22451e59a290"></a><table width="80%">
<caption><span>Adverse Reactions Reported for ≥1% of <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">Ventricular Arrhythmia</span> Patients N=2127</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<col align="center" valign="top" width="12%">
<thead>
<tr class="First TopRule">
<th class="Rrule" align="left"></th>
<th class="BotRule Rrule TopRule" align="center" colspan="3">Incidence by Total Daily Dose</th>
<th class="BotRule Rrule TopRule" align="center" rowspan="2">Total Incidence</th>
<th class="BotRule Lrule Rrule TopRule" align="center" rowspan="2">% of Pts. Who Discont.</th>
</tr>
<tr>
<th class="Rrule" align="left"></th>
<th class="BotRule Rrule" align="center">450 mg</th>
<th class="BotRule Rrule" align="center">600 mg</th>
<th class="BotRule Rrule" align="center">≥900 mg</th>
</tr>
<tr class="Last">
<th class="Rrule" align="left"></th>
<th class="Rrule" align="center">(N=1430)</th>
<th class="Rrule" align="center">(N=1337)</th>
<th class="Rrule" align="center">(N=1333)</th>
<th class="Rrule" align="center">(N=2127)</th>
<th class="Lrule Rrule" align="center"></th>
</tr>
</thead>
<tbody>
<tr class="BotRule First">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Lrule" align="center">4%</td>
<td class="Lrule" align="center">7%</td>
<td class="Lrule" align="center">11%</td>
<td class="Lrule" align="center">13%</td>
<td class="Lrule Rrule" align="center">2.4%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> and/or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">6%</td>
<td class="Lrule" align="center">9%</td>
<td class="Lrule" align="center">11%</td>
<td class="Lrule Rrule" align="center">3.4%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left">Unusual Taste</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">5%</td>
<td class="Lrule" align="center">6%</td>
<td class="Lrule" align="center">9%</td>
<td class="Lrule Rrule" align="center">0.7%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">4%</td>
<td class="Lrule" align="center">5%</td>
<td class="Lrule" align="center">7%</td>
<td class="Lrule Rrule" align="center">0.5%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">4%</td>
<td class="Lrule" align="center">6%</td>
<td class="Lrule Rrule" align="center">1.0%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">4%</td>
<td class="Lrule" align="center">5%</td>
<td class="Lrule Rrule" align="center">1.6%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">Proarrhythmia</span></td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">5%</td>
<td class="Lrule Rrule" align="center">4.7%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left">Angina</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">5%</td>
<td class="Lrule Rrule" align="center">0.5%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>(s)</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">5%</td>
<td class="Lrule Rrule" align="center">1.0%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred Vision</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">4%</td>
<td class="Lrule Rrule" align="center">0.8%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left">CHF</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">4%</td>
<td class="Lrule Rrule" align="center">1.4%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4103295" conceptname="Ventricular tachycardia">Ventricular Tachycardia</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule Rrule" align="center">1.2%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule Rrule" align="center">0.9%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">Palpitations</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule Rrule" align="center">0.5%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule Rrule" align="center">0.8%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV Block</span>, First Degree</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule Rrule" align="center">0.3%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">3%</td>
<td class="Lrule Rrule" align="center">0.6%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.7%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.2%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">Syncope</span>/<span class="product-label-link" type="condition" conceptid="4142895" conceptname="Near syncope">Near Syncope</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.7%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left">QRS Duration, Increased</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.5%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest Pain</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.2%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.4%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal Pain</span>, <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Cramps</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.4%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span></td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.2%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.3%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left">Premature Ventricular Contraction(s)</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.1%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.5%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">2%</td>
<td class="Lrule Rrule" align="center">0.6%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule Rrule" align="center">0.2%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span>(s)</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule Rrule" align="center">0.3%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Diaphoresis</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule Rrule" align="center">0.3%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="313791" conceptname="Bundle branch block">Bundle Branch Block</span></td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule Rrule" align="center">0.5%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule Rrule" align="center">0.2%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="313217" conceptname="Atrial fibrillation">Atrial Fibrillation</span></td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule Rrule" align="center">0.4%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule Rrule" align="center">0.1%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule Rrule" align="center">0.4%</td>
</tr>
<tr class="BotRule">
<td class="Lrule" align="left">Intraventricular Conduction Delay</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule Rrule" align="center">0.1%</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, Joints</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">0%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule" align="center">1%</td>
<td class="Lrule Rrule" align="center">0.1%</td>
</tr>
</tbody>
</table>
<p>In addition, the following adverse reactions were reported less frequently than 1% either in clinical trials or in marketing experience (<span class="Italics">adverse events for marketing experience are given in italics</span>). Causality and relationship to propafenone therapy cannot necessarily be judged from these events.</p>
<p><span class="Bold">Cardiovascular System: </span><span class="product-label-link" type="condition" conceptid="314665" conceptname="Atrial flutter">Atrial flutter</span>, <span class="product-label-link" type="condition" conceptid="4175473" conceptname="Atrioventricular dissociation">AV dissociation</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">hot flashes</span>, <span class="product-label-link" type="condition" conceptid="317302" conceptname="Sinus node dysfunction">sick sinus syndrome</span>, sinus pause or arrest, <span class="product-label-link" type="condition" conceptid="4275423" conceptname="Supraventricular tachycardia">supraventricular tachycardia</span>.</p>
<p><span class="Bold">Nervous System: </span> <span class="product-label-link" type="condition" conceptid="4304251" conceptname="Bizarre dreams">Abnormal dreams</span>, abnormal speech, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>,</span> <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>/<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (0.3%), <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, unusual smell sensation, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>.</p>
<p><span class="Bold">Gastrointestinal: </span> A number of patients with liver abnormalities associated with propafenone therapy have been reported in post-marketing experience. Some appeared due to <span class="product-label-link" type="condition" conceptid="4352876" conceptname="Liver damage">hepatocellular injury</span>, some were cholestatic and some showed a mixed picture. Some of these reports were simply discovered through clinical chemistries, others because of clinical symptoms including fulminant <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. One case was rechallenged with a positive outcome. <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">Cholestasis</span> (0.1%), elevated liver enzymes (alkaline phosphatase, serum transaminases) (0.2%), <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">gastroenteritis</span>, <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span> (0.03%).</p>
<p><span class="Bold">Hematologic: </span><span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">Agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>, <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="Italics">increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>,</span> <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>.
</p>
<p><span class="Bold">Other: </span><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span>, <span class="product-label-link" type="condition" conceptid="4049206" conceptname="Burning sensation in eye">eye irritation</span>, <span class="Italics"><span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>/<span class="product-label-link" type="condition" conceptid="4207539" conceptname="Syndrome of inappropriate vasopressin secretion">inappropriate ADH secretion</span>,</span> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, increased glucose, <span class="Italics"><span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">kidney failure</span>,</span> positive ANA (0.7%), <span class="Italics">lupus erythematosis,</span> <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle cramps</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="195314" conceptname="Nephrotic syndrome">nephrotic syndrome</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="over"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">The symptoms of overdosage, which are usually most severe within 3 hours of ingestion, may include <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, intra-atrial and intraventricular conduction disturbances, and rarely <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> and high grade <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmias</span>. Defibrillation as well as infusion of dopamine and isoproterenol have been effective in controlling rhythm and blood pressure. <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span> have been alleviated with intravenous diazepam. General supportive measures such as mechanical respiratory assistance and external cardiac massage may be necessary.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="dosage"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The dose of propafenone HCl must be individually titrated on the basis of response and tolerance. It is recommended that therapy be initiated with 150 mg propafenone given every eight hours (450 mg/day). Dosage may be increased at a minimum of 3 to 4 day intervals to 225 mg every 8 hours (675 mg/day) and, if necessary, to 300 mg every 8 hours (900 mg/day). The usefulness and safety of dosages exceeding 900 mg per day have not been established. In those patients in whom significant widening of the <span class="product-label-link" type="condition" conceptid="4064625" conceptname="QRS complex feature">QRS complex</span> or second or <span class="product-label-link" type="condition" conceptid="320744" conceptname="Complete atrioventricular block">third degree AV block</span> occurs, dose reduction should be considered.</p>
<p>As with other antiarrhythmic agents, in the elderly or in <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span> patients with marked previous myocardial damage, the dose of propafenone HCl should be increased more gradually during the initial phase of treatment.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Propafenone hydrochloride tablets are supplied as follows:</p>
<p>Propafenone hydrochloride tablets 150 mg, white, round, scored, film-coated, debossed MP 511</p>
<a name="i52cc3733-18bf-4792-8cec-41b39ab32c90"></a><table width="60%">
<col align="left" valign="top" width="65%">
<col align="left" valign="top" width="35%">
<tbody class="Headless">
<tr class="First">
<td align="left">Bottles of 20</td>
<td align="left">NDC 54868-4770-2</td>
</tr>
<tr>
<td align="left">Bottles of 30</td>
<td align="left">NDC 54868-4770-5</td>
</tr>
<tr>
<td align="left">Bottles of 60</td>
<td align="left">NDC 54868-4770-1</td>
</tr>
<tr>
<td align="left">Bottles of 90</td>
<td align="left">NDC 54868-4770-4<br>
</td>
</tr>
<tr class="Last">
<td align="left">Bottles of 100</td>
<td align="left">NDC 54868-4770-3<br>
</td>
</tr>
</tbody>
</table>
<p>Propafenone hydrochloride tablets 225 mg, white, round, scored, film-coated, debossed MP 512</p>
<a name="ia4f82609-6e15-4ef7-8f81-91582296e3e0"></a><table width="60%">
<col align="left" valign="top" width="65%">
<col align="left" valign="top" width="35%">
<tbody class="Headless">
<tr class="First">
<td align="left">Bottles of 30</td>
<td align="left">NDC 54868-5950-1</td>
</tr>
<tr>
<td align="left">Bottles of 90</td>
<td align="left">NDC 54868-5950-0<br>
</td>
</tr>
<tr class="Last">
<td align="left">Bottles of 60<br>
</td>
<td align="left">NDC 54868-5950-2<br>
</td>
</tr>
</tbody>
</table>
<br><div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<h2></h2>
<p class="First">Store at 20° to 25°C (68° to 77°F).</p>
<p>[See USP Controlled Room Temperature]</p>
<p>DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<h1></h1>
<p class="First">Manufactured by:<br>MUTUAL PHARMACEUTICAL CO., INC.<br>Philadelphia, PA 19124 USA</p>
<p>Rev 01, May 2009</p>
<br><p><br></p>
<p>Relabeling and Repackaging by:</p>
<p><span class="Bold">Physicians Total Care, Inc.</span><br>Tulsa, OK     74146<br></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 150 mg label</h1>
<p class="First"><span class="Bold"></span><span class="Bold"></span><span class="Bold">PROPAFENONE<br>HYDROCHLORIDE<br>TABLETS<br>150 mg</span></p>
<p><br><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="Principal Display Panel - 150 mg label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a7c8f090-c48c-44f7-9973-2cf4b491e35c&amp;name=150mg%20package%20label.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-15"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 225 mg label</h1>
<p class="First"><span class="Bold"></span><span class="Bold">PROPAFENONE<br>HYDROCHLORIDE<br>TABLETS<br>225 mg</span></p>
<p><br><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="Principal Display Panel - 225 mg label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a7c8f090-c48c-44f7-9973-2cf4b491e35c&amp;name=225mg%20package%20label.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROPAFENONE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">propafenone hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-4770(NDC:53489-551)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PROPAFENONE HYDROCHLORIDE</strong> (PROPAFENONE) </td>
<td class="formItem">PROPAFENONE HYDROCHLORIDE</td>
<td class="formItem">150 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYDEXTROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">9mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MP;511</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-4770-1</td>
<td class="formItem">60  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-4770-2</td>
<td class="formItem">20  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-4770-3</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">4</th>
<td class="formItem">NDC:54868-4770-4</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">5</th>
<td class="formItem">NDC:54868-4770-5</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075998</td>
<td class="formItem">05/18/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROPAFENONE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">propafenone hydrochloride tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:54868-5950(NDC:53489-552)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PROPAFENONE HYDROCHLORIDE</strong> (PROPAFENONE) </td>
<td class="formItem">PROPAFENONE HYDROCHLORIDE</td>
<td class="formItem">225 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARNAUBA WAX</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>HYPROMELLOSES</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYDEXTROSE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POLYETHYLENE GLYCOLS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>POVIDONE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>STARCH, CORN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>PROPYLENE GLYCOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM STARCH GLYCOLATE TYPE A POTATO</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>TITANIUM DIOXIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>TRIACETIN</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">white</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">10mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MP;512</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:54868-5950-0</td>
<td class="formItem">90  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:54868-5950-1</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">3</th>
<td class="formItem">NDC:54868-5950-2</td>
<td class="formItem">60  in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA075998</td>
<td class="formItem">10/09/2008</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Physicians Total Care, Inc.
							(194123980)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Physicians Total Care, Inc.</td>
<td class="formItem"></td>
<td class="formItem">194123980</td>
<td class="formItem">relabel(54868-4770, 54868-5950), repack(54868-4770, 54868-5950)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 12/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>c92c4adf-6ff2-4eda-a868-b0af18b08ae6</div>
<div>Set id: a7c8f090-c48c-44f7-9973-2cf4b491e35c</div>
<div>Version: 2</div>
<div>Effective Time: 20131206</div>
</div>
</div> <div class="DistributorName">Physicians Total Care, Inc.</div></p>
</body></html>
